PLANEGG and MUNICH, GERMANY / ACCESSWIRE / March 22, 2024 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced the receipt of U.S. antitrust clearance under the Hart-Scott-Rodino Antitrust...
MorphoSys AG (FSE: MOR; NASDAQ: MOR) reports results for the fourth quarter and the full year 2023. In 2023, we demonstrated the potential for pelabresib to shift the myelofibrosis treatment...